Trial Profile
An open-label, long term follow-up study with Keppra XR [levetiracetam] for treatment of partial-onset seizures.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2016
Price :
$35
*
At a glance
- Drugs Levetiracetam (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors UCB
- 13 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Sep 2009 Planned number of patients changed from 220 to 190 as reported by ClinicalTrials.gov.